Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
// Xuan-zhang Huang 1, * , You Chen 2, * , Jian Wu 1 , Xi Zhang 1 , Cong-cong Wu 1 , Chao-ying Zhang 1 , Shuang-shuang Sun 1 , Wen-jun Chen 1 1 Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou City 325027, P.R. China 2 The Wenzhou Dental Hospital, Wenzhou City 325027, P.R. China * Xuan-zhang Huang and You Chen contributed equally to this work Correspondence to: Wen-jun Chen, email: chenwenjun2233@126.com Keywords: aspirin, non-steroidal anti-inflammatory drugs, gastric cancer, chemoprevention, meta-analysis Received: July 25, 2016 Accepted: November 14, 2016 Published: November 25, 2016 ABSTRACT Background: The association between non-steroidal anti-inflammatory drugs (NSAIDs) and gastric cancer (GC) risk is controversial. The aim of this study is to evaluate the chemopreventive effect of NSAIDs for GC. Methods: A literature search was performed for relevant studies using the PubMed and Embase database (up to March 2016). Risk ratios (RRs) and 95% confidence intervals (CIs) were used as the effect measures. The dose–response analysis and subgroup analysis were also performed. Results: Twenty-four studies were included. Our results indicated that NSAIDs could reduce GC risk (any NSAIDs: RR=0.78, 96%CI=0.72-0.85; aspirin: RR=0.70, 95%CI=0.62-0.80; non-aspirin NSAIDs: RR=0.86, 95%CI=0.80-0.94), especially for non-cardia GC risk. Moreover, the dose-response analysis indicated the risk of GC decreased by 11% and 5% for 2 years increment of any NSAIDs and aspirin use, respectively. There were nonlinear relationships between the frequency of any NSAIDs use and aspirin use and GC risk (P for non-linearity<0.01), with a threshold effect of 5 times/week. A monotonically decreasing trend was observed only for the frequency of less than 5 times/week. Conclusions: Our results indicate that NSAIDs is inversely associated with GC risk, especially for non-cardia GC risk. NSAIDs use may become a feasible approach to prevent GC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for Trend Estimation from Summarized Dose-Response Data, with Applications to Meta-Analysis
Greenland, S., & Longnecker, M. P. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116237 · Cited by 2,353 · cited 1×
“A dose–response analysis was used to evaluate the relationship between duration and frequency of NSAIDs use and GC risk (Supplementary File S1) [62, 63].”
MethodRothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Gong, E. J., Ahn, J. Y., Jung, H., Lim, H., Choi, K., Lee, J. H., Kim, D. H., Choi, K. D., Song, H. J., Lee, G. H., et al. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12387 · Cited by 51
Cited by
Epidemiology of gastric cancer: global trends, risk factors and prevention
Rawla, P., & Barsouk, A. (2019) · Gastroenterology Review · doi:10.5114/pg.2018.80001 · Cited by 1,540
Pimentel-Nunes, P., Libânio, D., Marcos-Pinto, R., Areia, M., Leja, M., Esposito, G., Garrido, M., Kikuste, I., Megraud, F., Matysiak-Budnik, T., et al. (2019) · Endoscopy · doi:10.1055/a-0859-1883 · Cited by 993
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention
Thrift, A. P., Wenker, T. N., & El-Serag, H. B. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00747-0 · Cited by 828
Banks, M., Graham, D., Jansen, M., Gotoda, T., Coda, S., di Pietro, M., Uedo, N., Bhandari, P., Pritchard, D. M., Kuipers, E. J., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-318126 · Cited by 647
Tight junction proteins in gastrointestinal and liver disease
Zeisel, M. B., Dhawan, P., & Baumert, T. F. (2019) · Gut · doi:10.1136/gutjnl-2018-316906 · Cited by 358
Metadata
- Authors
- Huang, X.-Z., Chen, Y., Wu, J., Zhang, X., Wu, C.-C., Zhang, C.-Y., Sun, S.-S., & Chen, W.-J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-11-25
- Volume
- 8
- Issue
- 3
- Pages
- 4781-4795
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2554151104
- Cited by
- 75
- References
- 3
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.